See more : Shaftesbury Capital PLC (CCPPF) Income Statement Analysis – Financial Results
Complete financial analysis of NeuroSense Therapeutics Ltd. (NRSNW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeuroSense Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Blue World Acquisition Corporation (BWAQU) Income Statement Analysis – Financial Results
- Yeah Yeah Group Holdings Limited (8082.HK) Income Statement Analysis – Financial Results
- Tessenderlo Group NV (TSDOF) Income Statement Analysis – Financial Results
- China Evergrande Group (EV1.F) Income Statement Analysis – Financial Results
- Midsona AB (MSONBS.XD) Income Statement Analysis – Financial Results
NeuroSense Therapeutics Ltd. (NRSNW)
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 97.00K | 89.00K | 3.00K | 3.00K | 0.00 |
| Gross Profit | -97.00K | -89.00K | -3.00K | -3.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.27M | 6.42M | 3.08M | 2.50M | 898.00K |
| General & Administrative | 4.78M | 7.14M | 2.51M | 393.00K | 337.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.78M | 7.14M | 2.51M | 393.00K | 337.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.29M | 13.55M | 5.59M | 2.89M | 1.24M |
| Cost & Expenses | 10.29M | 13.55M | 5.59M | 2.89M | 1.24M |
| Interest Income | 178.00K | 91.00K | 0.00 | 61.00K | 18.00K |
| Interest Expense | 550.00K | 15.00K | 1.15M | 1.00K | 5.00K |
| Depreciation & Amortization | 97.00K | 89.00K | 3.00K | 3.00K | 1.24M |
| EBITDA | -10.63M | -13.38M | -2.88M | -2.83M | -1.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.05M | -13.55M | -5.59M | -2.89M | -1.24M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 769.00K | 1.21M | 1.55M | 60.00K | 13.00K |
| Income Before Tax | -11.28M | -12.34M | -4.04M | -2.83M | -1.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.14M | -1.55M | 1.00K | 5.00K |
| Net Income | -10.11M | -11.20M | -2.50M | -2.83M | -1.23M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.83 | -0.97 | -1.29 | -1.46 | -0.63 |
| EPS Diluted | -0.83 | -0.97 | -1.29 | -1.46 | -0.63 |
| Weighted Avg Shares Out | 13.64M | 11.50M | 1.94M | 1.94M | 1.94M |
| Weighted Avg Shares Out (Dil) | 13.64M | 11.50M | 1.94M | 1.94M | 1.94M |
Source: https://incomestatements.info
Category: Stock Reports